Erratum: KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia (Leukemia (2009) vol. 23 (492-500) 10.1038/leu.2008.365);KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia

Leukemia

Volumn 23, Issue 3, 2009, Pages 492-500

  Willemze, R ^a,b   Rodrigues, C A ^a   Labopin, M ^c   Sanz, G ^d   Michel, G ^e   Socie G ^a   Rio, B ^f   Sirvent, A ^g   Renaud, M ^h   Madero, L ⁱ   Mohty, M ^j   Ferra, C ^k   Garnier, F ^a,l   Loiseau, P ^a   Garcia, J ^m   Lecchi, L ⁿ   Kogler G ^o   Beguin, Y ^p   Navarrete, C ^q   Devos, T ^r   Ionescu, I ^a   Boudjedir, K ^a   Herr, A L ^a   Gluckman, E ^a   Rocha, V ^a,c   more..

^a SAINT LOUIS HOSPITAL   (France)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HÔPITAL SAINT ANTOINE   (France)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e TIMONE HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^h POITIERS UNIVERSITY HOSPITAL   (France)

ⁱ HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^j HÔTEL DIEU   (France)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l French Network of Cord Blood Banks   (France)

^m Barcelona Cord Blood Bank   (Spain)

ⁿ Eurocord José Carreras Stammzellbank ^*  (Italy)

^o Eurocord José Carreras Stammzellbank   (Germany)

^p Department of Haematology   (Belgium)

^q NHS Cord Blood Bank   (United Kingdom)

^r De Leuvense Navelstrengbloedbank   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HLA A ANTIGEN; HLA A11 ANTIGEN; HLA A3 ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOGENETICS; DONOR; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HISTOINCOMPATIBILITY; HUMAN; IMMUNOREACTIVITY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; RECIPIENT; REDUCED INTENSITY CONDITIONING; UMBILICAL CORD BLOOD;

EID: 62549084678     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.11     Document Type: Erratum

References (42)

1. Falkenburg JHF, Marijt WAF, Heemskerk MH, Willemze R. Minor histocompatibility antigens as target of graft-versus-leukemia reactions. Curr Opin Hematol 2002; 9: 497-502.
2. Kolb HJ, Schattenberg A, Goldman JM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
3. Farag SS, Fehninger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-1947.
4. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol 2004; 16: 626-633.
5. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5: 201-214.
6. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 2004; 34: 1673-1679.
7. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K et al Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
8. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer alloreactivity in mismatched haematopoietic transplants. Science 2002; 295: 2097-2100.
9. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T et al Donor natural killer cell allorecognition of missing self in haploidentical hematopoieitc transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110: 433-440.
10. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819.
11. Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005; 105: 2594-2600.
12. Hsu K, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K et al Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884.
13. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JC et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002; 100: 3825-3827.
14. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: A report from the center for international blood and bone marrow transplant research, the European blood and bone marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006; 12: 876-884.
15. Bornhauser M, Schwerdtfeger R, Marin H, Frank KH, Theuser C, Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004; 103: 2860-2861.
16. Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004; 103: 1521-1526.
17. Sun JY, Dagis A, Gaidulis L, Miller MM, Rodriquez R, Parker P et al Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic stem cell transplantation for leukaemia patients. Biol Blood Marrow Transplant 2007; 13: 197-205.
18. Gluckman E, Rocha V. History of the clinical use of umbilical cord blood hematopoietic cells. Cytotherapy 2005; 7: 219-227.
19. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351 2276-2285.
20. Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Curr Opin Immunol 2006; 18: 565-570.
21. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: A comparison study. The Lancet 2007; 369: 1947-1954.
22. Ruggeri L, Capanni M, Mancusi A, Urbani E, Perroccio K, Burcgielli E et al. Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation. Blood Cells Mol Dis 2004; 33: 216-221.
23. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GvHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
24. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A longterm clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
25. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
26. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 116: 1141-1154.
27. Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
28. Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F et al Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002; 63: 271-280.
29. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS et al Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174: 6540-6545.
30. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644-650.
31. Lowe EJ, Turner V, Handgretinger R, Horwitz EM, Benaim E, Hale GA et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003; 123: 323-326.
32. Kloosterboer FM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Similar potential to become activated and proliferate but differential kinetics and profiles of cytokine production of umbilical cord blood T cells and adult blood naive and memory T cells. Hum Immunol 2006; 67: 874-883.
33. Szabolcs P, Niedzwiecki D. Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 2007; 9: 111-122.
34. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370-4376.
35. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109: 5058-5061.
36. Hsu K, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD et al KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12: 828-836.
37. Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006; 82: 1024-1030.
38. Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura-Ishii S, Tanaka H et al. Japan Marrow Donor Program. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 2008; 14: 75-87.
39. Elmaagacli AH, Ottinger H, Koldehoff M, Peceny R, Steckel NK, Trenschel R et al. Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Transplantation 2005; 79: 1741-1747.
40. Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005; 129: 631-643.
41. Dawson MA, Spencer A. Successful use of haploidentical stem-cell transplantation with KIR mismatch as initial therapy for poor-risk myelodysplastic syndrome. J Clin Oncol 2005; 23: 4473-4474.
42. Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA et al Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 2: 331-342.